Matthew Strobeck Buys 40,000 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck bought 40,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $56,000.00. Following the purchase, the director now directly owns 2,606,879 shares in the company, valued at approximately $3,649,630.60. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Biodesix Stock Performance

Shares of Biodesix stock opened at $1.33 on Friday. The company has a current ratio of 3.40, a quick ratio of 3.28 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a 12-month low of $1.15 and a 12-month high of $2.21. The business’s 50 day moving average is $1.69 and its 200-day moving average is $1.61.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same period in the prior year, the firm posted ($0.12) earnings per share. On average, equities research analysts predict that Biodesix, Inc. will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Biodesix

Institutional investors and hedge funds have recently modified their holdings of the company. CVI Holdings LLC bought a new position in Biodesix during the second quarter worth about $59,000. Opaleye Management Inc. boosted its stake in shares of Biodesix by 7.7% during the 1st quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after acquiring an additional 38,157 shares during the period. Perkins Capital Management Inc. boosted its stake in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after acquiring an additional 310,000 shares during the period. Essex Investment Management Co. LLC increased its holdings in shares of Biodesix by 1.4% during the 1st quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company’s stock worth $1,324,000 after acquiring an additional 12,669 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in Biodesix in the 2nd quarter valued at $2,874,000. 20.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Craig Hallum assumed coverage on shares of Biodesix in a report on Friday, July 26th. They issued a “buy” rating and a $3.00 price objective on the stock. Scotiabank initiated coverage on shares of Biodesix in a research report on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Biodesix presently has an average rating of “Buy” and a consensus target price of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.